Get started
Author

Célestine Simand

Observed names: C. Simand, Celestine Simand, Simand, C., Simand, Célestine
Observed institutions: Centre National de la Recherche Scientifique, Inserm, University of California, San Francisco, Université Clermont Auvergne, Institut de génétique et de biologie moléculaire et cellulaire, Institut de Cancérologie Strasbourg, Centre Hospitalier Universitaire de Limoges, Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Saint-Louis, Hôpitaux Universitaires de Strasbourg, Hôpital d'Hautepierre, UCSF Helen Diller Family Comprehensive Cancer Center, Centre Henri Becquerel, Laboratoire d'hématologie, Université de Strasbourg
ORCID: 0000-0002-2643-358X
Observed ORCID: 0000-0002-2643-358X
OpenAlex ID: A5063206095
Invasive Pulmonary Aspergillosis
2020 · Marie-Pierre Ledoux, Blandine Guffroy, et al. · Seminars in Respiratory and Critical Care Medicine · 141
Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults
2020 · Marie-Anne Couturier, Xavier Thomas, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 63
Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey
2018 · Pierre Bories, Sébastien Lamy, et al. · Haematologica · 42
PDF
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2022 · Vincent Marmouset, Justine Decroocq, et al. · Clinical Cancer Research · 33
PDF
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment
2024 · Sylvain Garciaz, Pierre‐Yves Dumas, et al. · American Journal of Hematology · 26
PDF
Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia
2022 · Frédéric Baron, Myriam Labopin, et al. · Bone Marrow Transplantation · 25
Factors associated with coinfections in invasive aspergillosis: a retrospective cohort study
2021 · François Danion, Céline Duval, et al. · Clinical Microbiology and Infection · 25
PDF
Real-world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting, gram negative bacilli infections: a case series
2022 · Baptiste Hoellinger, Célestine Simand, et al. · Clinical Microbiology and Infection · 24
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
2020 · Pierre Bories, Naïs Prade, et al. · PLoS ONE · 22
PDF
Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC
2022 · Paul Chauvet, Annalisa Paviglianiti, et al. · Bone Marrow Transplantation · 21
PDF
Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series
2026 · Marc Scherlinger, Yannick Dieudonné, et al. · Annals of the Rheumatic Diseases · 20
PDF
Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party
2020 · Ali Bazarbachi, Myriam Labopin, et al. · Transplantation and Cellular Therapy · 19
Comparison of Short- and Long-Term Mortality in Patients with or without Cancer Admitted to the ICU for Septic Shock: A Retrospective Observational Study
2022 · Pierrick Le Borgne, Léa Feuillassier, et al. · Cancers · 17
PDF
Ikaros cooperates with Notch activation and antagonizes TGFβ signaling to promote pDC development
2018 · Jérôme Mastio, Célestine Simand, et al. · PLoS Genetics · 17
PDF
Intermediate-Dose Cytarabine as Postinduction AML Therapy
2025 · Mathilde Hunault, Cécile Pautas, et al. · NEJM Evidence · 16
Ikaros antagonizes DNA binding by STAT5 in pre-B cells
2020 · Beate Heizmann, Stéphanie Le Gras, et al. · PLoS ONE · 16
PDF
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS
2025 · Amy E. DeZern, Sylvain Thepot, et al. · Blood Advances · 15
PDF
Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study
2023 · Sylvain Garciaz, Sarah Bertoli, et al. · Blood · 15
Allogeneic stem cell transplantation for acquired pure red cell aplasia
2019 · Constantijn Halkes, Liesbeth C de Wreede, et al. · American Journal of Hematology · 15
PDF
Blinatumomab + Ponatinib for Relapsed Ph1-Positive Acute Lymphoblastic Leukemia: The French Experience
2018 · Marie-Anne Couturier, Xavier Thomas, et al. · Blood · 15
Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry
2024 · Claire Lacan, Jérôme Lambert, et al. · Journal of Hematology & Oncology · 14
PDF
Concomitant haemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID‐19 and acute promyelocytic leukaemia
2020 · Mathieu Baldacini, Raoul Pop, et al. · British Journal of Haematology · 14
PDF
Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
2022 · Louise Laloi, Natacha Chaumard Billotey, et al. · Cancer Medicine · 12
PDF
Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial
2020 · Olivier Tournilhac, Magali Le Garff-Tavernier, et al. · Haematologica · 12
PDF
Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
2021 · Andreas Rank, Christophe Peczynski, et al. · Transplantation and Cellular Therapy · 11
Works count: 102
Citation count: 762
H-index: 16
I10-index: 26
Year
Topic
Type